Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Melanoma/Skin Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.

Shailender Bhatia

TPS9605

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).

Jeffrey S. Weber

9502

Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.

Morganna Louise Freeman

9594

Confirmatory trial of non-amputative digit preservation surgery in subungual melanoma: JCOG1602 (J-NAIL study).

Yasuhiro Nakamura

TPS9607

Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.

James M. G. Larkin

9591

Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).

Maria Gonzalez

TPS9604

Effect of combination immunotherapy on tumor growth, survival, and intratumoral immune infiltration in transgenic murine model of melanoma.

Robyn Denise Gartrell

e21610

Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.

Dirk Schadendorf

9590

Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.

Ulrike M. Leiter

9501

Gene expression profiling with a 31-gene test to identify a population of melanoma patients with a low sentinel lymph node biopsy positive rate.

Eddy C. Hsueh

e21611

Impact of surveillance-detected metastatic recurrence on treatment outcomes of high-risk melanoma.

Michael Ong

e21612

Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.

Alexander Noor Shoushtari

9593

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

Robert Hans Ingemar Andtbacka

9508

Liver-directed treatment for patients with uveal melanoma hepatic metastasis: A retrospective analysis of overall survival.

Rino S Seedor

9592

Mohs micrographic surgery in Uruguay: Our first 130 cases for skin cancer.

Julio César Magliano

e21617

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Elisa A. Rozeman

TPS9606

Phase Ⅲ randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.

Bin Lian

9589

Reflectance confocal microscopy and melanocytic lesions: The road to saving a biopsy.

Ann Mary John

e21614

SWOG S1512: A phase II and pilot trial of pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM).

Kari Lynn Kendra

TPS9608

Use of radiation in high risk population with non melanoma skin cancer at a rural cancer center.

Shikha Prakash

e21613

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).

Laurent Mortier

9509